The estimated Net Worth of William Mc Dowall Wells is at least $92.7 Mille dollars as of 21 November 2014. William Wells owns over 5,810 units of Acadia Pharmaceuticals Inc stock worth over $92,670 and over the last 13 years William sold ACAD stock worth over $0.
William has made over 4 trades of the Acadia Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently William exercised 5,810 units of ACAD stock worth $7,902 on 21 November 2014.
The largest trade William's ever made was exercising 30,000 units of Acadia Pharmaceuticals Inc stock on 2 September 2014 worth over $40,800. On average, William trades about 6,667 units every 18 days since 2012. As of 21 November 2014 William still owns at least 5,810 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of William Wells stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 3911 SORRENTO VALLEY BLVD., SAN DIEGO, CA, 92121.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... e Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: